Genmab A GMAB
NASDAQ GMAB
$43.79 +3.79 (+9.48%)
At close: Oct 23, 2026 · 4:00 PM EDT

Genmab A (GMAB) Asset Writedowns and Impairment (2024 - 2025)

Updated

Genmab A (GMAB) posted Asset Writedowns and Impairment of $32 million for the year ended Dec 31, 2025, up 88.2% from $17 million a year earlier.

Analysis

Genmab A (GMAB) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends

  • Business Quant data shows GMAB's Asset Writedowns and Impairment at $17 million in the year ended Dec 31, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Genmab A 2.87 Bn -2.51 Bn 1.07 Bn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 1.00 Mn
Mar 31, 2024 9.00 Mn
API Access

Genmab A Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=GMAB&period=max&api_key=YOUR_API_KEY